TOP-5 Price Targets by Analysts on 11.03.26

Alumis Inc. [US0223071020] Raymond James initiates coverage with "Strong Buy" and price target of $46 (63% upside potential) The basis of this positive assessment is primarily the company's leading active ingredient, Envudeucitinib, a highly selective TYK2 inhibitor that, according to analysts, is excellently positioned to gain a significant market share in the field of oral, non-biologic therapies for moderate to severe plaque psoriasis. The expectation is that Envudeucitinib will clearly stand out against existing and upcoming competitive...